Microba Life Sciences Future Growth
Future criteria checks 5/6
Microba Life Sciences is forecast to grow earnings and revenue by 45.7% and 38.5% per annum respectively. EPS is expected to grow by 54.5% per annum. Return on equity is forecast to be 11.1% in 3 years.
Key information
45.7%
Earnings growth rate
54.5%
EPS growth rate
| Healthcare earnings growth | 25.2% |
| Revenue growth rate | 38.5% |
| Future return on equity | 11.1% |
| Analyst coverage | Low |
| Last updated | 03 Nov 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 40 | 3 | N/A | 1 | 2 |
| 6/30/2026 | 24 | -19 | N/A | -16 | 2 |
| 6/30/2025 | 18 | -18 | N/A | -13 | 2 |
| 6/30/2024 | 12 | -20 | -20 | -16 | N/A |
| 3/31/2024 | 9 | -19 | -22 | -18 | N/A |
| 12/31/2023 | 7 | -18 | -23 | -20 | N/A |
| 9/30/2023 | 6 | -16 | -19 | -16 | N/A |
| 6/30/2023 | 5 | -13 | -15 | -12 | N/A |
| 3/31/2023 | 5 | -12 | -15 | -12 | N/A |
| 12/31/2022 | 5 | -11 | -14 | -11 | N/A |
| 9/30/2022 | 5 | -11 | -13 | -11 | N/A |
| 6/30/2022 | 5 | -11 | -12 | -10 | N/A |
| 3/31/2022 | 4 | -11 | -11 | -10 | N/A |
| 12/31/2021 | 4 | -11 | -9 | -9 | N/A |
| 9/30/2021 | 4 | -9 | -9 | -8 | N/A |
| 6/30/2021 | 4 | -8 | -8 | -7 | N/A |
| 6/30/2020 | 3 | -7 | -5 | -4 | N/A |
| 6/30/2019 | 2 | -5 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MAP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MAP is expected to become profitable in the next 3 years.
Revenue vs Market: MAP's revenue (38.5% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: MAP's revenue (38.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MAP's Return on Equity is forecast to be low in 3 years time (11.1%).